NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
Clinical Trials
5 trialsNCT06408194 2026-02-10
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
Phase 1 Recruiting
NCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT05541341 2025-06-06
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Novartis
Recruiting